

IN THE SPECIFICATION**AMENDMENTS TO THE SPECIFICATION**

1. Please amend paragraph 18 as follows:

[0018] or a bombesin analog according to the formula:

-Gln-Trp-Ala-Ala-βAla -His-Phe-Nle-NH<sub>2</sub>; (SEQ ID NO: 8)  
 -Gln-Trp-Ala-Val-Gly-His-Leu-Ψ(CH<sub>2</sub>-NH)-Leu-NH<sub>2</sub>; (SEQ ID NO: 9)  
 -Gln-Trp-Ala-Val-Gly-His-Leu-Ψ(CH<sub>2</sub>-NH)-Phe-NH<sub>2</sub>; (SEQ ID NO: 10)  
 -Gln-Trp-Ala-Val-βAla-His-Leu-Leu-NH<sub>2</sub>; (SEQ ID NO: 11)  
 -Gln-Trp-Ala-Val-βAla-His-Leu-Nle-NH<sub>2</sub>; (SEQ ID NO: 12)  
 -Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH<sub>2</sub>; (SEQ ID NO: 13)  
 -Gln-Trp-Ala-Val-βAla -His-Ala-Nle-NH<sub>2</sub>; (SEQ ID NO: 14)  
 -Gln-Trp-Ala-Val-βAla -Ala-Phe-Nle-NH<sub>2</sub>; (SEQ ID NO: 15)  
 -Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH<sub>2</sub>; (SEQ ID NO: 1)  
 -Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH<sub>2</sub>; (SEQ ID NO: 2)  
 -Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH<sub>2</sub>; (SEQ ID NO: 3)  
 -DAla-Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Ala-βAla-His-Phe-Nle-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-βAla-Ala-Phe-Nle-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Ala-Nle-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Leu-Leu-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Leu-Nle-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-Ψ(CH<sub>2</sub>-NH)-Leu-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-Ψ(CH<sub>2</sub>-NH)-Phe-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH<sub>2</sub>; or

or a pharmaceutically acceptable salt thereof.

2. Please delete the original Sequence Listing and insert the Substitute Sequence Listing included herewith.